Tokyo Tape
Sign in
← PeptiDream

Quarterly report · Q3

4587.TEDINET S100PLL7
Period2022-01-01 → 2022-09-30
Filed2022-11-11
StandardIFRS
ConsolidatedYes
Data checks17 of 17 passed
Key figures · 65
MetricValuePeriodScopeSource row
Revenue¥11.2bn2022-01-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥6.2bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥9.4bn2021-01-01 → 2021-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥7.8bn2021-01-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥4.9bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income−¥427m2022-01-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥1.2bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥4.0bn2021-01-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥3.6bn2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax−¥369m2022-01-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.2bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥3.8bn2021-01-01 → 2021-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥3.8bn2021-01-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥3.5bn2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)−¥187m2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥946m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥2.6bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥2.5bn2021-01-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥2.5bn2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥187m2022-01-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥946m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥2.6bn2021-01-01 → 2021-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥2.5bn2021-01-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥2.5bn2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥51.3bnat 2022-09-30Cons.Assets IFRS
Total assets¥27.0bnat 2021-12-31Cons.Assets IFRS
Total assets¥28.1bnat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total assets¥26.1bnat 2020-12-31dCons.Assets IFRS
Total liabilities¥26.8bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥1.7bnat 2021-12-31Cons.Liabilities IFRS
Total liabilities¥4.9bnat 2020-12-31dCons.Liabilities IFRS
Net assets / equity¥24.5bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥25.4bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥25.2bnat 2021-09-30Cons.Equity IFRS
Net assets / equity¥21.3bnat 2020-12-31dCons.Equity IFRS
Equity (owners)¥24.5bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥25.4bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥25.2bnat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥21.3bnat 2020-12-31dCons.Equity attributable to owners of parent IFRS
Cash & equivalents¥4.6bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.7bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥12.2bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥7.1bnat 2020-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥1.4bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥6.7bn2021-01-01 → 2021-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥6.6bn2021-01-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥27.0bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥2.3bn2021-01-01 → 2021-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥1.7bn2021-01-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥20.9bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥66m2021-01-01 → 2021-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥45m2021-01-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-1.442022-01-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥7.282022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥19.962021-01-01 → 2021-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥19.252021-01-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥19.132021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥-1.442022-01-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥7.282022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.812021-01-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥19.062021-01-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.122021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio47.7%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio93.8%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio89.4%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 13
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-09-30−¥8m
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-09-30−¥8m
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥3.6bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥3.6bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥197m
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥7.6bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥7.6bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2022-01-01 → 2022-09-30¥8m
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-09-30¥183m
—segment totalrevenue2022-01-01 → 2022-09-30¥11.2bn
—segment totalrevenue external2022-01-01 → 2022-09-30¥11.2bn
—segment totalrevenue intersegment2022-01-01 → 2022-09-30¥8m
—segment totalsegment profit2022-01-01 → 2022-09-30−¥14m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 629
ItemContextValueUnit
Share based payment transactions ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Share based payment transactions ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember－JPY
Share based payment transactions ss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Share based payment transactions ss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember392277000JPY
Share based payment transactions ss IFRSPrior1YTDDuration392277000JPY
Total transactions with owners IFRSPrior1YTDDuration_ShareCapitalIFRSMember22852000JPY
Total transactions with owners IFRSPrior1YTDDuration_CapitalSurplusIFRSMember415130000JPY
Total transactions with owners IFRSPrior1YTDDuration_TreasurySharesIFRSMember30221000JPY
Total transactions with owners IFRSPrior1YTDDuration_RetainedEarningsIFRSMember-24175000JPY
Total transactions with owners IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember24175000JPY
Total transactions with owners IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember468204000JPY
Total transactions with owners IFRSPrior1YTDDuration468204000JPY
Equity IFRSPrior1QuarterInstant_ShareCapitalIFRSMember3956738000JPY
Equity IFRSPrior1QuarterInstant_CapitalSurplusIFRSMember10720437000JPY
Equity IFRSPrior1QuarterInstant_TreasurySharesIFRSMember-625162000JPY
Equity IFRSPrior1QuarterInstant_RetainedEarningsIFRSMember9955159000JPY
Equity IFRSPrior1QuarterInstant_OtherComponentsOfEquityIFRSMember1155002000JPY
Equity IFRSPrior1QuarterInstant_EquityAttributableToOwnersOfParentIFRSMember25162175000JPY
Equity IFRSPrior1QuarterInstant25162175000JPY
Equity IFRSPrior1YearInstant_ShareCapitalIFRSMember3956738000JPY
Equity IFRSPrior1YearInstant_CapitalSurplusIFRSMember4452358000JPY
Equity IFRSPrior1YearInstant_TreasurySharesIFRSMember-620123000JPY
Equity IFRSPrior1YearInstant_RetainedEarningsIFRSMember16372687000JPY
Equity IFRSPrior1YearInstant_OtherComponentsOfEquityIFRSMember1188589000JPY
Equity IFRSPrior1YearInstant_EquityAttributableToOwnersOfParentIFRSMember25350250000JPY
Equity IFRSPrior1YearInstant25350250000JPY
Profit loss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember-186603000JPY
Profit loss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-186603000JPY
Profit loss IFRSCurrentYTDDuration-186603000JPY
Other comprehensive income IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_RetainedEarningsIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-709440000JPY
Other comprehensive income IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-709440000JPY
Other comprehensive income IFRSCurrentYTDDuration-709440000JPY
Comprehensive income IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Comprehensive income IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Comprehensive income IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Comprehensive income IFRSCurrentYTDDuration_RetainedEarningsIFRSMember-186603000JPY
Comprehensive income IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-709440000JPY
Comprehensive income IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-896044000JPY
Comprehensive income IFRSCurrentYTDDuration-896044000JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember-87000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 17 of 17 passed
balance sheet identityconsolidated 2020-12-31pass
balance sheet identityconsolidated 2021-12-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass